冠科美博Apollomics |DJSeedin创新合作峰会临床公司路演汇报

冠科美博是一家生物科技公司，旨在成为抗肿瘤新药开发的全球领导者。在美国和中国两地均开展业务，在中国杭州及上海设立实体机构。在杭州设有办公室、实验室、宿舍以及一个临床开发团队，以支持我们开展临床前及临床开发项目。在这两个技术中心的深厚根基使我们能够通过内部创新及外部合作为中国及全球的患者开发新的癌症疗法。具备良好的条件以探索针对耐药及难以治疗癌症的解决方案。

Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics currently has a pipeline of nine drug candidates across multiple programs, six of which are currently in the clinical stage of development. Apollomics’ lead programs include investigating its core product, vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States, and developing an anti-cancer enhancer drug candidate, uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia and other hematologic cancers, which is currently in Phase 1 and Phase 3 clinical trials in China.